6c311e15_egy_Appendix___The_White_House__Action_Item_Description
[Action Item Number] 3.2.A [Action Item Name] Support the Development of New Medications for Addiction [Lead Agency] HHS [Component(s)] NIDA [Action Item Description] 
The effectiveness of addiction treatment has been hampered by the limited range of available FDA-approved medications relative to other chronic medical disorders. Read more Fortunately, advances in neuroscience research are identifying promising directions for medication development. New medications include those that help in the acute management of withdrawal symptoms and those that reduce craving for drugs on an ongoing basis. Recent scientific work has also indicated another potential line of productive medication development: vaccines that block the ability of consumed drugs to reach the brain, thereby reducing their reinforcing power. NIDA will continue its funding of medication development research and, in partnership with ONDCP, will identify ways to increase private sector investment in addiction medication development.
ONDCP Strategy Appendix | The White House
Action Item Description